We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$493M
Cap. Flow %
11.96%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.47%
2 Consumer Discretionary 10.25%
3 Technology 2.5%
4 Real Estate 1.29%
5 Materials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLE icon
126
CALL
State Street Energy Select Sector SPDR ETF
XLE
$39B
$1.5M 0.04%
100,000
– –
ORTX
127
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.45M 0.04%
35,150
-1,850
-5% -$95.6K
CTMX icon
128
CytomX Therapeutics
CTMX
$690M
$1.19M 0.03%
178,600
-9,400
-5% -$69.7K
BLU
129
DELISTED
BELLUS Health Inc.
BLU
$1.08M 0.03%
475,000
+331,237
+230% +$939K
IRWD icon
130
Ironwood Pharmaceuticals
IRWD
$586M
$994K 0.02%
110,532
– –
RIGL icon
131
Rigel Pharmaceuticals
RIGL
$723M
$771K 0.02%
32,110
-1,690
-5% -$41.5K
CDTX
132
DELISTED
Cidara Therapeutics
CDTX
$640K 0.02%
11,234
-591
-5% -$41.7K
PASG icon
133
Passage Bio
PASG
$14.5M
$205K 0.01%
782
-10,918
-93% -$3.76M
AAL icon
134
American Airlines Group
AAL
$9.82B
– –
-1,500,000
Closed -$18.8M
AGIO icon
135
Agios Pharmaceuticals
AGIO
$2.08B
– –
-376,000
Closed -$20.1M
AKBA icon
136
Akebia Therapeutics
AKBA
$338M
– –
-574,000
Closed -$7.79M
ALEC icon
137
Alector
ALEC
$169M
– –
-200,000
Closed -$4.89M
ALNY icon
138
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-100,000
Closed -$14.8M
ASND icon
139
Ascendis Pharma A/S
ASND
$16.5B
– –
-65,000
Closed -$9.61M
AVTR icon
140
Avantor
AVTR
$9.82B
– –
-2,000,000
Closed -$34M
BNTX icon
141
CALL
BioNTech
BNTX
$23.5B
– –
-150,000
Closed -$10M
BPMC
142
DELISTED
Blueprint Medicines
BPMC
– –
-550,000
Closed -$42.9M
CYRX icon
143
CryoPort
CYRX
$753M
– –
-89,000
Closed -$2.69M
DAL icon
144
CALL
Delta Air Lines
DAL
$56.7B
– –
-1,250,000
Closed -$35.1M
DNTH icon
145
Dianthus Therapeutics
DNTH
$5.69B
– –
-28,125
Closed -$3.38M
HTHT icon
146
Huazhu Hotels Group
HTHT
$13.3B
– –
-175,000
Closed -$6.13M
IDYA icon
147
IDEAYA Biosciences
IDYA
$3.43B
$0 ﹤0.01%
8
-239,296
-100% -$2.96M
MLCO icon
148
CALL
Melco Resorts & Entertainment
MLCO
$2.21B
– –
-500,000
Closed -$7.76M
NKTR icon
149
Nektar Therapeutics
NKTR
$2.39B
– –
-15,933
Closed -$5.54M
PYPL icon
150
PayPal
PYPL
$50.3B
– –
-200,000
Closed -$34.8M
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $493M of net new capital in Q3 2020, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 62% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was argenx, an estimated $30.2M trimmed.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.